Nordea Investment Management AB Boosts Eli Lilly Stake

Institutional investor raises position in pharmaceutical giant by 8% in Q4 2025

Mar. 24, 2026 at 9:38am

Got story updates? Submit your updates here. ›

Nordea Investment Management AB, a major European asset manager, increased its stake in Eli Lilly and Company by 8% in the fourth quarter of 2025, according to a recent 13F filing. Nordea now owns 1,479,977 shares of the pharmaceutical company, making it one of Eli Lilly's largest institutional investors.

Why it matters

Eli Lilly is a bellwether pharmaceutical stock, and major investment moves by large institutional investors like Nordea can signal broader market sentiment and confidence in the company's future performance and growth prospects.

The details

Nordea Investment Management AB raised its position in Eli Lilly by purchasing an additional 109,980 shares during the fourth quarter. This increased Nordea's total stake in Eli Lilly to 1,479,977 shares, or approximately 0.16% of the company's outstanding stock. Nordea is now the 8th largest institutional shareholder of Eli Lilly.

  • Nordea increased its Eli Lilly stake in the fourth quarter of 2025.

The players

Nordea Investment Management AB

A major European asset management firm that oversees over $400 billion in client assets.

Eli Lilly and Company

A global pharmaceutical company headquartered in Indianapolis, Indiana that develops and markets a range of medicines and therapies.

Got photos? Submit your photos here. ›

The takeaway

Nordea's increased investment in Eli Lilly signals continued confidence from a major institutional investor in the pharmaceutical company's growth potential and future performance. This could indicate broader market optimism around Eli Lilly's product pipeline and commercial execution.